C9orf50 and colorectal carcinoma: As more detailed evaluations of the clinical performance for detecting different stages of CRC were not reported for most of the other markers, the sensitivities of methylated C9orf50 and methylated KCNQ5 for early stage CRC (stage 0 to II) could only be compared to those of methylated SEPT9 and methylated SDC2, which were very similar among all four methylation markers, 87.4% for methylated C9orf50, 82.1% for methylated KCNQ5, 90.1 and 81.5% for methylated SEPT9 (46, 50), and 88.9 and 89.1% for methylated SDC2 (25, 46).